Ultravist 370 Injection 50 mL

Ultravist 240 Injection helps to visualize the blood vessels more clearly.
Side effects
Major & minor side effects for Ultravist 370 Injection 50 mL

Headache

Feeling of warmth or heat

Back pain

Chest pain

Abnormal vision

Frequent urge to urinate

Pale skin at injection site

Decreased heart rate rare

Nausea or Vomiting rare

Increased thirst rare

Tingling of the hands or feet rare

Difficulty in breathing rare

Bluish lips or skin rare

Uses of Ultravist 370 Injection 50 mL
What is it prescribed for?

Digital subtraction angiography
Ultravist 240 Injection is used as contrast media in digital subtraction angiography.

Cerebral arteriography
Ultravist 240 Injection is used as contrast media in cerebral arteriography.

Visceral angiography
Ultravist 240 Injection is used as contrast media in visceral angiography.

Peripheral arteriography
Ultravist 240 Injection is used as contrast media in peripheral arteriography.

Peripheral venography
Ultravist 240 Injection is used as contrast media in peripheral venography.

Coronary arteriography
Ultravist 240 Injection is used as contrast media in coronary arteriography.

Excretory urography
Ultravist 240 Injection is used as contrast media in excretory urography.

Contrast computed tomography
Ultravist 240 Injection is used as contrast media in contrast computed tomography.

Left ventriculography
Ultravist 240 Injection is used as contrast media in left ventriculography.

Concerns

Frequently asked questions

Onset of action
The amount of time taken by Ultravist 240 Injection to show its effect is subject to vary based on the individual, strength, and intended use.

Duration of Effect
The amount of time for which Ultravist 240 Injection remains effective is subject to vary based on the individual, strength, and intended use.

Safe with Alchohol?
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Is it habit forming?
No habit-forming tendencies were reported.

Usage in pregnancy?
Ultravist 240 Injection is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before receiving Ultravist 240 Injection.

Usage while breast-feeding?
Ultravist 240 Injection is not recommended for use in breastfeeding women unless necessary. The risks and benefits should be discussed with the doctor before receiving Ultravist 240 Injection.

When not to use?

Allergy
Ultravist 240 Injection is not recommended for use if you have a known allergy to Ultravist 370 Injection 50 mL or any other inactive ingredients present along with it.

Intrathecal Administration
Ultravist 240 Injection is not recommended for intrathecal administration (into the spine).

Preparatory dehydration
Prolonged fasting and bowel preparation before Ultravist 240 Injection is not recommended in children due to the risk of kidney failure.

Warnings

Warnings for special population

Pregnancy
Ultravist 240 Injection is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before receiving Ultravist 240 Injection.

Breast-feeding
Ultravist 240 Injection is not recommended for use in breastfeeding women unless necessary. The risks and benefits should be discussed with the doctor before receiving Ultravist 240 Injection.

General Warnings

Kidney injury
Use of Ultravist 240 Injection may increase the risk of kidney injury and hence should be used with caution in patients with kidney diseases due to the risk of worsening of the patient’s condition. Close monitoring of kidney function, appropriate dose adjustments, or replacement with a suitable alternative might be required in some cases.

Hyperthyroidism
Ultravist 240 Injection should be used with caution in patients with hyperthyroidism due to the risk of worsening of the patient’s condition. Close monitoring of thyroid function, appropriate dose adjustments, or replacement with a suitable alternative might be required in some cases.

Severe local tissue damage
Extravasation during injection may result in severe local tissue damage in some patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.

Severe cutaneous adverse reactions
Use of Ultravist 240 Injection may cause severe cutaneous adverse reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, etc. in some patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.

Anaphylactoid
Use of Ultravist 240 Injection may cause fatal anaphylactoid reactions, especially in patients with allergic disorders. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be required in some cases based on the clinical condition of the patient.

Dosage

Missed Dose
Since Ultravist 240 Injection is given during procedures, therefore the likelihood of missing a dose is very less.

Overdose
Since Ultravist 240 Injection is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very less. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.

Interactions
Interaction with Medicines

Beta blockers moderate

Cyclosporine severe

Ibuprofen severe

General Instructions

Ultravist 240 Injection is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Inform the doctor if you have a known allergy Ultravist 240 Injection. Report all your current medicines as well as your medical conditions to the doctor before receiving Ultravist 240 Injection.

Other details

Usage does not depend on food timings

To be taken as instructed by doctor

Effect on sleep is not established

References

drugbank –
Iopromide [Internet].
Available from: https://go.drugbank.com/drugs/DB09156
[cited 12/12/2020].
December 11, 2020